{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:19:48Z","timestamp":1789579188417,"version":"build-2803163510"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T00:00:00Z","timestamp":1675382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Ras guanine nucleotide-releasing protein 2 (RASGRP2), one of the guanine nucleotide exchange factors (GEFs), has attracted much attention in recent years. However, the correlation between RASGRP2 and immune infiltration and malignant features in lung adenocarcinoma (LUAD) has rarely been mentioned.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The Limma package and the LASSO regression model were performed to screen for differentially expressed genes. Data from the TCGA and 5 GEO databases were used to explore the expression level of RASGRP2 in LUAD patients. A weighted co-expression network and LinkFinder module were established to find the related genes of RASGRP2. The ESTIMATE algorithm was used to analyze the correlation between RASGRP2 and immune infiltration in LUAD. Tumor-infiltrating immune cells were sorted and sequenced at the single-cell level to analyze differences in RASGRP2. Real-time PCR and immunohistochemistry were performed in the real-world cohort to verify the expression of RASGRP2 and its correlation with immune-related genes. Clone formation and EdU assays were used to verify the proliferation ability. The proportion of apoptotic cells was analyzed by flow cytometry. Observation of mitochondrial membrane potential (MMP) changes by fluorescence microscopy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Our results suggested that decreased RASGRP2 was associated with worse clinical parameters and prognosis in LUAD patients. And we constructed a FLI1-HSA-miR-1976-RASGRP2 transcriptional network to support the role of RASGRP2. Enrichment analysis revealed that RASGRP2 was involved in lymphocyte activation and leukocyte adhesion. RASGRP2 was found to be positively correlated with the infiltration of most immune cells, immunoregulators, and chemokines in a subsequent study. Meanwhile, the real-world cohort confirmed that the expression levels of PDCD1, CTLA4, CD40LG, CCL14, CXCR5, and CCR7 were higher in the high-RASGRP2 expression group. Cytological experiments proved that RASGRP2 inhibited cell proliferation in LUAD by regulating mitochondrial-dependent apoptosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>RASGRP2 was a potential immune-related biomarker of LUAD. In addition, RASGRP2 was involved in the malignant progression of LUAD through the regulation of mitochondrial-dependent apoptosis.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1100231","type":"journal-article","created":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T07:17:34Z","timestamp":1675408654000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["RASGRP2 is a potential immune-related biomarker and regulates mitochondrial-dependent apoptosis in lung adenocarcinoma"],"prefix":"10.3389","volume":"14","author":[{"given":"Yongting","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyang","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changjing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA: Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.05.043","article-title":"Integrative proteomic characterization of human lung adenocarcinoma","volume":"182","author":"Xu","year":"2020","journal-title":"Cell"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13168","article-title":"Targeting KRAS mutant lung cancer: light at the end of the tunnel","volume":"16","author":"Drosten","year":"2022","journal-title":"Mol Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00383-1","article-title":"Revisiting neoadjuvant therapy in non-small-cell lung cancer","volume":"22","author":"Saw","year":"2021","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12885-018-4075-5","article-title":"Frequency of the acquired resistant mutation T790 m in non-small cell lung cancer patients with active exon 19Del and exon 21 L858R: a systematic review and meta-analysis","volume":"18","author":"Wang","year":"2018","journal-title":"BMC Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2018.01.148","article-title":"Current outcomes of postrecurrence survival in patients after resection of non-small cell lung cancer","volume":"10","author":"Mizuno","year":"2018","journal-title":"J Thorac Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"384","DOI":"10.3390\/cancers13030384","article-title":"Immune resistance in lung adenocarcinoma","volume":"13","author":"Spella","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.03.018","article-title":"The 2021 global lung cancer therapy landscape","volume":"17","author":"Deb","year":"2022","journal-title":"J Thorac Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.06.001","article-title":"Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches","volume":"32","author":"Reck","year":"2021","journal-title":"Ann Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1152\/physrev.00003.2012","article-title":"Regulation of small GTPases by GEFs, GAPs, and GDIs","volume":"93","author":"Cherfils","year":"2013","journal-title":"Physiol Rev"},{"key":"B12","doi-asserted-by":"publisher","first-page":"5599","DOI":"10.3390\/cancers13225599","article-title":"Oncogenic KRAS: Signaling and drug resistance","volume":"13","author":"Kim","year":"2021","journal-title":"Cancers"},{"key":"B13","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13045-021-01127-w","article-title":"Emerging strategies to target RAS signaling in human cancer therapy","volume":"14","author":"Chen","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20130477","article-title":"Human CalDAG-GEFI gene (RASGRP2) mutation affects platelet function and causes severe bleeding","volume":"211","author":"Canault","year":"2014","journal-title":"J Exp Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1601734","DOI":"10.1183\/13993003.01734-2016","article-title":"Molecular biomarkers for lung adenocarcinoma","volume":"49","author":"Calvayrac","year":"2017","journal-title":"Eur Respir J"},{"key":"B16","doi-asserted-by":"publisher","first-page":"624","DOI":"10.3390\/cells9030624","article-title":"DNA Methylation-based testing in liquid biopsies as detection and prognostic biomarkers for the four major cancer types","volume":"9","author":"Const\u00e2ncio","year":"2020","journal-title":"Cells"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2016.04.100","article-title":"A negative-feedback loop regulating ERK1\/2 activation and mediated by RasGPR2 phosphorylation","volume":"474","author":"Ren","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20130131","article-title":"Phosphorylation of the guanine-nucleotide-exchange factor CalDAG-GEFI by protein kinase a regulates Ca(2+)-dependent activation of platelet Rap1b GTPase","volume":"453","author":"Guidetti","year":"2013","journal-title":"Biochem J"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12271","article-title":"Phosphorylation of CalDAG-GEFI by protein kinase a prevents Rap1b activation","volume":"11","author":"Subramanian","year":"2013","journal-title":"J Thromb Haemost"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-714048","article-title":"Temporal quantitative phosphoproteomics of ADP stimulation reveals novel central nodes in platelet activation and inhibition","volume":"129","author":"Beck","year":"2017","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30406-5","article-title":"Predictive biomarkers for checkpoint inhibitor-based immunotherapy","volume":"17","author":"Gibney","year":"2016","journal-title":"Lancet Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"109905","DOI":"10.1016\/j.celrep.2021.109905","article-title":"FARP1, ARHGEF39, and TIAM2 are essential receptor tyrosine kinase effectors for Rac1-dependent cell motility in human lung adenocarcinoma","volume":"37","author":"Cooke","year":"2021","journal-title":"Cell Rep"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.320580","article-title":"The role of ras guanine nucleotide releasing protein 4 in fc epsilonRI-mediated signaling, mast cell function, and T cell development","volume":"287","author":"Zhu","year":"2012","journal-title":"J Biol Chem"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(02)00451-X","article-title":"RasGRP1 transduces low-grade TCR signals which are critical for T cell development, homeostasis, and differentiation","volume":"17","author":"Priatel","year":"2002","journal-title":"Immunity"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/79766","article-title":"RasGRP is essential for mouse thymocyte differentiation and TCR signaling","volume":"1","author":"Dower","year":"2000","journal-title":"Nat Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003798","article-title":"Critical roles of RasGRP1 for invariant NKT cell development","volume":"187","author":"Shen","year":"2011","journal-title":"J Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1502107","article-title":"RasGRP1 and RasGRP3 are required for efficient generation of early thymic progenitors","volume":"197","author":"Golec","year":"2016","journal-title":"J Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/art.38924","article-title":"Ras guanine nucleotide-releasing protein 4 is aberrantly expressed in the fibroblast-like synoviocytes of patients with rheumatoid arthritis and controls their proliferation","volume":"67","author":"Kono","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-218768","article-title":"CalDAG-GEFI is at the nexus of calcium-dependent platelet activation","volume":"114","author":"Stefanini","year":"2009","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/nm1098","article-title":"CalDAG-GEFI integrates signaling for platelet aggregation and thrombus formation","volume":"10","author":"Crittenden","year":"2004","journal-title":"Nat Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.3390\/ijms21031075","article-title":"RasGRP2 structure, function and genetic variants in platelet pathophysiology","volume":"21","author":"Canault","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1038\/s41598-021-82619-0","article-title":"RasGRP2 inhibits glyceraldehyde-derived toxic advanced glycation end-products from inducing permeability in vascular endothelial cells","volume":"11","author":"Takino","year":"2021","journal-title":"Sci Rep"},{"key":"B33","doi-asserted-by":"publisher","first-page":"11129","DOI":"10.3390\/ijms222011129","article-title":"The role of RASGRP2 in vascular endothelial cells-a mini review","volume":"22","author":"Takino","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B34","doi-asserted-by":"publisher","first-page":"16717","DOI":"10.1038\/s41598-019-53419-4","article-title":"The inhibition of bax activation-induced apoptosis by RasGRP2 via r-Ras-PI3K-Akt signaling pathway in the endothelial cells","volume":"9","author":"Takino","year":"2019","journal-title":"Sci Rep"},{"key":"B35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40246-020-00265-5","article-title":"Hydroxymethylation and tumors: can 5-hydroxymethylation be used as a marker for tumor diagnosis and treatment","volume":"14","author":"Xu","year":"2020","journal-title":"Hum Genomics"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.7150\/thno.28119","article-title":"Non-invasive diagnosis of early-stage lung cancer using high-throughput targeted DNA methylation sequencing of circulating tumor DNA (ctDNA)","volume":"9","author":"Liang","year":"2019","journal-title":"Theranostics"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2014.04.082","article-title":"GSTP1 promoter methylation is associated with recurrence in early stage prostate cancer","volume":"192","author":"Maldonado","year":"2014","journal-title":"J Urol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-00577-5","article-title":"The cutting-edge progress of immune-checkpoint blockade in lung cancer","volume":"18","author":"Zhou","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1808","article-title":"Therapeutic targeting of the tumor microenvironment","volume":"11","author":"Bejarano","year":"2021","journal-title":"Cancer Discovery"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.669474","article-title":"Differentiation and regulation of T cells: A balancing act for cancer immunotherapy","volume":"12","author":"Basu","year":"2021","journal-title":"Front In Immunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3892\/ijo.2021.5230","article-title":"Immunological modulation of the Th1\/Th2 shift by ionizing radiation in tumors (Review)","volume":"59","author":"Li","year":"2021","journal-title":"Int J Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1172\/JCI80011","article-title":"Anti-PD-1\/PD-L1 therapy of human cancer: past, present, and future","volume":"125","author":"Chen","year":"2015","journal-title":"J Clin Invest"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0915174107","article-title":"PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors","volume":"107","author":"Curran","year":"2010","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B44","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/d41573-019-00214-5","article-title":"Immune agonist antibodies face critical test","volume":"19","author":"Garber","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002131","article-title":"Generation of a safe and efficacious llama single-domain antibody fragment (vHH) targeting the membrane-proximal region of 4-1BB for engineering therapeutic bispecific antibodies for cancer","volume":"9","author":"Zhai","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005018","article-title":"Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies","volume":"10","author":"H\u00e4gerbrand","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2019.08.010","article-title":"Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity","volume":"10","author":"Fu","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.09.023","article-title":"The JAK-STAT pathway at 30: Much learned, much more to do","volume":"185","author":"Philips","year":"2022","journal-title":"Cell"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/mc.23174","article-title":"PYCR1 knockdown inhibits the proliferation, migration, and invasion by affecting JAK\/STAT signaling pathway in lung adenocarcinoma","volume":"59","author":"Gao","year":"2020","journal-title":"Mol Carcinog"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgac046","article-title":"PSMA5 contributes to progression of lung adenocarcinoma in association with the JAK\/STAT pathway","volume":"43","author":"Lu","year":"2022","journal-title":"Carcinogenesis"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2012.03.014","article-title":"JAK and STAT signaling molecules in immunoregulation and immune-mediated disease","volume":"36","author":"O'Shea","year":"2012","journal-title":"Immunity"},{"key":"B52","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.3390\/cancers11122002","article-title":"JAK-STAT signaling: A double-edged sword of immune regulation and cancer progression","volume":"11","author":"Owen","year":"2019","journal-title":"Cancers"},{"key":"B53","doi-asserted-by":"publisher","first-page":"114760","DOI":"10.1016\/j.bcp.2021.114760","article-title":"Targeting the JAK-STAT pathway in autoimmune diseases and cancers: A focus on molecular mechanisms and therapeutic potential","volume":"193","author":"Tzeng","year":"2021","journal-title":"Biochem Pharmacol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1100231\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T07:17:39Z","timestamp":1675408659000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1100231\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,3]]},"references-count":53,"alternative-id":["10.3389\/fimmu.2023.1100231"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1100231","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,3]]},"article-number":"1100231"}}